GlassScriptPhysician profile
Thomas T Katta
NPI 1205934288
$22,190.72
in general payments reported to CMS, 2019-2025
82 companies · $3,423 in 2025
The $3,423 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,273 · 2020: $2,150 · 2021: $3,233 · 2022: $3,369 · 2023: $3,706 · 2024: $4,036 · 2025: $3,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,966.84 |
| Education | $198.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,668.87 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Incyte Corporation | $1,582.90 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $1,570.09 | 2019-2025 | |
| Celgene Corporation | $1,230.98 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $1,224.19 | 2019-2025 | Erleada, Akeega, Balversa |
| Pfizer INC. | $1,138.53 | 2019-2025 | |
| Astellas Pharma US INC | $1,024.03 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Merck Sharp & Dohme LLC | $952.34 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $885.64 | 2019-2025 | Opdivo, Reblozyl, Eliquis |
| Genzyme Corporation | $853.94 | 2019-2025 | |
| Lilly USA, LLC | $683.03 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $599.81 | 2019-2024 | Tukysa, Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $583.10 | 2019-2025 | |
| Daiichi Sankyo INC. | $518.39 | 2019-2025 | Enhertu, Vanflyta, Datroway |
| Eisai INC. | $450.26 | 2020-2025 |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $396.35 | 2020-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $392.76 | 2019-2025 | Fruzaqla, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $364.24 | 2019-2025 | Libtayo |
| Glaxosmithkline, LLC. | $331.85 | 2020-2025 | Ojjaara, Shingrix |
| Puma Biotechnology, INC. | $331.20 | 2019-2025 | Nerlynx |
| Array Biopharma INC | $324.85 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $316.23 | 2019-2023 | Imbruvica |
| Blueprint Medicines Corporation | $221.60 | 2022-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.94 | 2019-2022 | |
| Amgen INC. | $218.63 | 2020-2023 | Lumakras |
| Taiho Oncology, INC. | $217.86 | 2019-2025 | |
| Kite Pharma, INC. | $211.47 | 2020-2025 | Yescarta |
| Janssen Pharmaceuticals, INC | $194.28 | 2019-2024 | Xarelto |
| Abbvie INC. | $193.41 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $193.07 | 2022-2025 | Ultomiris |
| Sobi, INC | $174.43 | 2022-2025 | |
| Genentech USA, INC. | $170.35 | 2019-2024 | Venclexta, Rozlytrek, Gavreto |
| Jazz Pharmaceuticals INC. | $169.81 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $147.78 | 2024-2025 | Pyrukynd |
| Genmab U.S., INC. | $133.95 | 2024-2025 | Epkinly |
| Exelixis INC. | $124.80 | 2019-2024 | Cabometyx |
| Johnson & Johnson Health Care Systems INC. | $115.00 | 2019 | |
| Beigene USA, INC. | $111.62 | 2022-2024 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $109.40 | 2024-2025 | Provenge |
| Dova Pharmaceuticals | $104.76 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $101.48 | 2023-2025 | Orgovyx |
| Stemline Therapeutics INC. | $83.36 | 2023-2024 | Orserdu |
| Epizyme, INC. | $82.66 | 2020-2022 | |
| G1 Therapeutics, INC. | $81.77 | 2022 | |
| Gilead Sciences, INC. | $74.40 | 2019-2025 | Trodelvy |
| Foundation Medicine, INC. | $72.90 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $68.88 | 2020-2024 | |
| Tersera Therapeutics LLC | $54.65 | 2023-2025 | Quzyttir, Zoladex |
| Deciphera Pharmaceuticals INC. | $53.83 | 2020-2025 | Romvimza, Qinlock |
| Beone Medicines USA, INC. | $50.89 | 2025 | Brukinsa |
| Springworks Therapeutics, INC. | $49.64 | 2024-2025 | Ogsiveo |
| Myovant Sciences INC. | $49.38 | 2021-2022 | |
| Adc Therapeutics America, INC. | $47.46 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $46.68 | 2024-2025 | |
| Geron Corporation | $45.70 | 2025 | Rytelo |
| Verastem, INC. | $45.60 | 2019 | |
| Fennec Pharmaceuticals, INC. | $44.35 | 2024-2025 | Pedmark, Fyarro |
| Rigel Pharmaceuticals, INC. | $44.07 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacosmos Therapeutics INC. | $43.77 | 2021-2024 | Cosela |
| Cti Biopharma Corp. | $43.67 | 2022-2023 | Vonjo |
| Emd Serono, INC. | $41.70 | 2020-2023 | Bavencio |
| Heron Therapeutics, INC. | $40.61 | 2022 | |
| Alnylam Pharmaceuticals INC. | $36.90 | 2021 | |
| Emmaus Medical, INC. | $34.67 | 2019-2021 | |
| Verity Pharmaceuticals INC. | $33.88 | 2023-2024 | Trelstar |
| Caris Mpi, INC. | $33.65 | 2025 | Mi Cancer Seek |
| Amag Pharmaceuticals, INC. | $33.10 | 2019 | |
| Eusa Pharma (US) LLC | $30.99 | 2019 | |
| Morphosys, US INC. | $30.29 | 2021 | |
| Pharmaessentia USA Corporation | $24.33 | 2025 | Besremi |
| Recordati_rare_diseases_inc. | $22.43 | 2025 | Enjaymo |
| Mirati Therapeutics, INC. | $22.32 | 2023 | Krazati |
| Tolmar Pharmaceuticals, INC. | $20.41 | 2022 | |
| Tolmar, INC. | $19.96 | 2023 | |
| Kyowa Kirin, INC. | $18.69 | 2021 | |
| Gt Medical Technologies, INC | $18.55 | 2023 | Gammatile |
| Syndax Pharmaceuticals, INC. | $17.85 | 2025 | |
| Clovis Oncology, INC. | $16.92 | 2019 | |
| Global Blood Therapeutics, INC. | $16.78 | 2022 | |
| Grifols USA, LLC | $15.89 | 2019 | |
| Tempus Ai, INC | $15.86 | 2025 | Xt Cdx |
| Kerecis Limited | $5.06 | 2021 |
Drugs and devices associated with these payments
Enhertu $627Reblozyl $579Keytruda $564Jakafi $506Lenvima $372Verzenio $343Xtandi $327Sarclisa $276Nubeqa $270Lynparza $266Fruzaqla $259Kisqali $257Jaypirca $247Xpovio $236Libtayo $226Ayvakit $226Tukysa $225Braftovi $217Erleada $207Pomalyst $204Orgovyx $200Mektovi $194Lorbrena $185Imfinzi $180Imbruvica $175Vitrakvi $174Stivarga $174Welireg $165Epkinly $159Venclexta $157Bosulif $153Retevmo $152Pyrukynd $148Opdivo $147Balversa $147Akeega $147Talzenna $146Brukinsa $145Ojjaara $137Padcev $133Elrexfio $124Vonjo $119Pluvicto $117Rybrevant $117Piqray $113Comirnaty $111Inlyta $111Provenge $109Adcetris $103Paxlovid $96.97Zepzelca $88.71Ibrance $86.42Darzalex $86.34Orserdu $83.36Nerlynx $78.75Scemblix $65.28Doptelet $63.13Inqovi $62.41Lonsurf $62.41Fabhalta $61.41Promacta $60.80Vanflyta $60.09Yescarta $57.82Opdualag $49.83Ogsiveo $49.64Bavencio $48.06Lutathera $47.15Fotivda $46.68Rytelo $45.70Lumakras $45.05Oxbryta $44.73Gavreto $41.65Enjaymo $40.84Zynyz $40.07Monjuvi $40.07Xarelto $38.62Mekinist $36.45Jevtana $35.85Eliquis $35.13Trelstar $33.88Mi Cancer Seek $33.65Ninlaro $33.41Tasigna $33.08Cabometyx $29.99Quzyttir $29.58Elitek $28.77Trodelvy $27.74Zynlonta $27.73Keytruda Qlex $27.40Shingrix $26.50Tavalisse $26.31Rezlidhia $26.31Tecvayli $26.04Vyloy $25.64Zoladex $25.07Besremi $24.33Pedmark $23.37Krazati $22.32Cosela $22.23Datroway $22.03
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Katta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.